Angeli Andrea, Ferraroni Marta, Capasso Clemente, Supuran Claudiu T
NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Florence, Italy.
Department of Chemistry "Ugo Schiff″, University of Florence,Via della Lastruccia 3-13,I-50019 Sesto Fiorentino,Florence, Italy.
ACS Med Chem Lett. 2025 Feb 10;16(3):483-486. doi: 10.1021/acsmedchemlett.5c00034. eCollection 2025 Mar 13.
In this study, we provide the first evidence that sonepiprazole, a dopamine D receptor antagonist, acts as a potent inhibitor of human carbonic anhydrases (hCAs). Sonepiprazole exhibited significant inhibitory activity across the panel of catalytically active hCAs, with the exception of hCA IV, and hCA III. The most potent inhibition was observed against the brain-associated isoform hCA VII, with a of 2.9 nM. Insights from X-ray crystallographic structures of the complexes with hCA I, hCA II, and hCA XII revealed that the sulfonamide group of sonepiprazole coordinates the zinc ion in the active site, a typical interaction for this class of inhibitors. Despite the presence of isoform-specific residues at the rim of the active site pocket, these variations seem not to significantly impact the compound overall inhibition potency. These findings highlight a dual functionality of sonepiprazole as both a D receptor antagonist and a carbonic anhydrase inhibitor.
在本研究中,我们首次证明了多巴胺D受体拮抗剂索奈哌唑可作为人碳酸酐酶(hCAs)的强效抑制剂。除hCA IV和hCA III外,索奈哌唑在一系列具有催化活性的hCAs中均表现出显著的抑制活性。观察到对脑相关同工型hCA VII的抑制作用最强,IC50为2.9 nM。对与hCA I、hCA II和hCA XII形成的复合物的X射线晶体结构分析表明,索奈哌唑的磺酰胺基团与活性位点中的锌离子配位,这是这类抑制剂的典型相互作用。尽管活性位点口袋边缘存在同工型特异性残基,但这些差异似乎并未对化合物的整体抑制效力产生显著影响。这些发现突出了索奈哌唑作为D受体拮抗剂和碳酸酐酶抑制剂的双重功能。